| Terminated | Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers NCT04083170 | Fred Hutchinson Cancer Center | Phase 2 |
| Active Not Recruiting | Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Ac NCT03399773 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candid NCT05972577 | Ohio State University Comprehensive Cancer Center | N/A |
| Withdrawn | Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer NCT03739606 | City of Hope Medical Center | Phase 2 |
| Completed | 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II NCT03941769 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Genomics Study in CML Patients With Ponatinib Treatment NCT06945146 | Dong-Wook Kim | — |
| Completed | A Mobile Intervention (txt4TKI) for the Improvement of Tyrosine Kinase Inhibitor Management in Patients With C NCT04694820 | Thomas Jefferson University | N/A |
| Completed | DISCO Application for the Improvement of Financial Outcomes in Patients With Hematologic Cancer NCT04282343 | Barbara Ann Karmanos Cancer Institute | N/A |
| Active Not Recruiting | Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant NCT03622788 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndr NCT03630991 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Pa NCT03333486 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients W NCT03096782 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transpla NCT03267186 | Andrew Rezvani | Phase 2 |
| Terminated | Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia NCT03195010 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in P NCT03128359 | City of Hope Medical Center | Phase 2 |
| Terminated | Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Pa NCT02877082 | Emory University | Phase 2 |
| Terminated | Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia NCT02730195 | Emory University | Phase 2 |
| Withdrawn | Long Term Effects of Tyrosine Kinase Inhibitor Therapy on Ovarian Reserve and Fertility in Patients With Chron NCT02734823 | University of Southern California | — |
| Completed | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in NCT01858740 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Ther NCT01751425 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hemato NCT01789255 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies NCT01760655 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Withdrawn | Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Posit NCT01670084 | Mayo Clinic | Phase 2 |
| Terminated | Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to NCT01426334 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer W NCT00796068 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML NCT00702403 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases NCT00351975 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia NCT01445080 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Posi NCT00316953 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patient NCT00719888 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia NCT00101088 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Ce NCT00096161 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer NCT00060372 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia NCT00054431 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia NCT00049192 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia NCT00030394 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction NCT00025415 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Tr NCT00036738 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia NCT00023920 | National Cancer Institute (NCI) | Phase 2 |
| Completed | STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia NCT00015834 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferent NCT02210858 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia NCT00006364 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leuke NCT00003694 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by NCT00003145 | Fred Hutchinson Cancer Center | Phase 2 |